Fennec Pharmaceuticals Inc.

NASDAQ:FENC

4.65 (USD) • At close October 17, 2024
Bedrijfsnaam Fennec Pharmaceuticals Inc.
Symbool FENC
Munteenheid USD
Prijs 4.65
Beurswaarde 127,222,605
Dividendpercentage 0%
52-weken bereik 4.09 - 11.92
Industrie Biotechnology
Sector Healthcare
CEO Mr. Rostislav Raykov
Website https://www.fennecpharma.com

An error occurred while fetching data.

Over Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals

Vergelijkbare Aandelen

Clene Inc. logo

Clene Inc.

CLNN

5.34 USD

Savara Inc. logo

Savara Inc.

SVRA

3.65 USD

High Tide Inc. logo

High Tide Inc.

HITI

2.55 USD

Compugen Ltd. logo

Compugen Ltd.

CGEN

1.73 USD

NeuroPace, Inc. logo

NeuroPace, Inc.

NPCE

6.39 USD

Quipt Home Medical Corp. logo

Quipt Home Medical Corp.

QIPT

3.02 USD

Vor Biopharma Inc. logo

Vor Biopharma Inc.

VOR

0.717 USD

Harvard Bioscience, Inc. logo

Harvard Bioscience, Inc.

HBIO

2.39 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)